Kaya Ltd
NSE:KAYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Q1-2026 Earnings Call
AI Summary
Earnings Call on Aug 6, 2025
Revenue Growth: Kaya's clinic business collections grew 7% year-on-year, while overall revenue from operations rose 1% to INR 52.8 crores in Q1 FY '26.
Profitability Drop: The company posted a stand-alone loss after tax of INR 14.2 crores versus a profit of INR 6.4 crores last year, which included a one-time gain.
Product & Service Mix: The product business grew 11% and the services business grew 6%, with strong momentum in categories like Bath & Body, Nutraceuticals, Sun Care, Hair Care, and Pigmentation.
Expansion & Investment: Opened 2 new clinics and invested in 31 new dermatology machines as part of ongoing brand refresh and innovation efforts.
Fundraising Update: Shifted from a planned rights issue to a preferential allotment of INR 75 crores for faster capital raising, with the rights issue still under consideration.
Customer Experience: NPS score remained high at 90, and over 90% of collections came from the Kaya Smiles loyalty program.
Kaya reported a 7% growth in clinic business collections and 11% growth in product business, mainly from Bath & Body, Nutraceuticals, and Sun Care categories. Service business collections grew 6%, with strong performances in Acne & Scars, Hair Care, Anti-aging, and Pigmentation. Overall revenue growth was modest at 1% year-on-year.
The company swung to a stand-alone loss after tax of INR 14.2 crores compared to a profit of INR 6.4 crores a year earlier, which had included a one-time gain. Management addressed rising employee benefit expenses and consumable costs, attributing them to wage increases, expansion, and a shift in service mix towards higher-consumable treatments.
Kaya continued its expansion, opening two new clinics in Bangalore and Noida, each achieving a 5-star Google rating. The company invested in 31 new dermatology machines for anti-aging, pigmentation, acne, hair care, and body services, reflecting a focus on service innovation and capacity.
Kaya shifted its fundraising plan from a rights issue of up to INR 300 crores to a preferential allotment of INR 75 crores for faster execution, bringing in a strategic investor. The rights issue remains under consideration for the future, pending board decision after the current round closes.
Kaya maintained a high NPS score of 90, indicating strong customer satisfaction. The Kaya Smiles loyalty program was a major contributor, accounting for over 90% of clinic collections, with experiential marketing and free services targeted at top-tier loyalty members.
Management discussed efforts to increase clinic utilization without significant additional costs, aiming to improve profitability by driving higher customer counts, especially on weekdays. The company is investing in marketing and automation to boost new customer acquisition.
The company is measuring returns on marketing spend by tracking new customer acquisition. A 6% rise in new customer count was noted, attributed to increased performance marketing efforts, with the aim to drive more customers to existing clinics and support bottom-line growth.
Ladies and gentlemen, good day, and welcome to the Kaya Q1 FY '26 Earnings Conference Call. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Sachin Bobade from Dolat Capital. Thank you, and over to you, sir.
Thank you, Vishaka. On behalf of Dolat Capital, I welcome you all to the Q1 FY '26 Earnings Conference of Kaya Limited. Hope you all and your family members are staying safe and healthy. From the management side, we have with us Mr. Rajiv Suri, Global Chief Executive Officer; and Mr. Arihant Dhariwal, Chief Financial Officer. Now I hand the floor to the management for their opening remarks, and then we would have question-and-answer session. Over to you, sir.
Thank you. Good evening. I would like to welcome you to the conference call on company's behalf. The investor presentation has been uploaded on the stock exchanges and contains the financials, key metrics and business updates. I hope you have had a chance to go through it. Let me begin the conference call with the highlights of quarter 1 performance.
Our clinic business registered a 7% collection growth over quarter 1 FY '25. Clinic product business witnessed an 11% growth versus quarter 1 FY '25, mainly driven by categories like Bath & Body, Nutraceuticals and Sun Care. Services business registered collection growth of 6% over quarter 1 FY '25, mainly driven by categories like Acne & Scars, Hair care, and Anti-aging, Hair free and Brightening and Pigmentation. Hair care and Brightening and Pigmentation also maintained a healthy growth of 20% and 13% respectively. Our NPS scores continue to trend higher in quarter 1 FY '26 at 90, reflecting Kaya's great customer experience.
A quick update on other initiatives. On expansion, Kaya launched 2 new clinics in quarter 1, Yelahanka in Bangalore and Starling Mall in Noida. Yelahanka clinic was inaugurated by Kannada film star Sapthami Gowda, a leading celebrity in South. It is the 12th clinic in Bangalore, enjoying a 5-star Google rating. Starling Mall Clinic was inaugurated by Shalini Passi, an A-list celebrity based in Delhi. The clinic is also enjoying a 5-star Google rating. On our brand refresh program to uplift customer experience and outcome we invested in 31 new dermatology machines in Anti-aging, Brightening and Pigmentation, Acne, Hair care, Body and Laser Hair Reduction in quarter 1 FY '26. Innovation remains core to our business and performed strongly, new product development contributes to 5% of the clinic collections. New service development contributed to 6% of Kaya India clinic collections, use of marketing automation, including WhatsApp bot and Web bot helped improve customer experience. The chatbots enable a seamless customer journey for appointments and clinic information.
With regards to our Kaya Smiles Loyalty Program, Kaya Smiles contributed more than 90% of Kaya clinics collections in quarter 1 FY '26. We focus on experiential marketing for our Kaya Smiles platinum and Kaya Smiles gold elite based by giving free services, which helped us grow collections.
On the financial performance, revenue from operations at a stand-alone level is INR 52.8 crores for quarter 1 FY '26, a growth of 1% over the corresponding quarter 1 FY '25. Stand-alone loss after tax and other comprehensive income for quarter 1 FY '26 was negative INR 14.2 crores as compared to after-tax profit of INR 6.4 crores over corresponding quarter Q1 FY '25, which included a onetime gain of INR 15.8 crores for reversal of impairment on investment and sale of intellectual property. The detailed financial information update is already with you in the uploaded investor presentation, and you may refer to that for additional information on the performance.
I now open the session for questions and my colleagues and I will be glad to answer it.
[Operator Instructions] The first question is from the line of Rehan Saiyyed from Trinetra Asset Managers.
I have 2 questions mainly on the P&L side. First is given that net employee benefit has risen to over [indiscernible].
Sorry, Rehan, your voice is not clear.
Okay. So first question is on the employee benefit side. So your employee benefit has risen to over 16 to 24 lakh this quarter. Can you help us -- are there some additional drivers of this increase is just leading to clinic expansion, wage inflation or higher productivity incentives?
Sorry, your voice is cracking.
Do I mention my question again, Sir?
Yes. And I understood that you're asking some increase on the employee benefit cost in the P&L.
Yes. [indiscernible] expansion due to inflation or higher productivity [indiscernible].
Yes, I will answer your question on that. What is the second question?
My second question is, sir, on the standalone assuming the consumable cost is still higher at [ 88 lakhs ]. Are there any ongoing initiatives to increase procured efficiency or optimize inventory without affecting service quality? Just put some light on that.
Yes, I understood both of the question. Yes. So I'll answer your first question. So with respect to increase in employee benefit expenses, there are 2 or 3 factors by which the cost has increased. One is there is a factor of increment as compared to last year. And also, yes, a bit of productivity has increased and there was some contest, which was been run along with the new clinics, which have been part of the employee benefit cost. That's the reason why the employee benefit cost has increased as compared to last year. With respect to consumables, our market mix has changed a bit. Our body contouring, our acne scars, anti-aging categories have grown a bit as compared to last year, where the consumers are a bit higher, and that is the reason of increasing consumable cost.
Okay. Okay, sir. And sir, last if you can allow one more question on the estimate markets [indiscernible].
Sorry to interrupt you, Rehan sir. I will request you to come back in the queue for the follow-up question. The next question is from the line of Madhur Rathi from Counter Cyclical Investments.
I'm trying to understand, in our last quarter, you mentioned that our clinic level EBITDA is 26%, 27%, but most of that goes away into corporate cost and marketing cost. Sir, I'm trying to understand what is our utilization level currently? And sir, a steady-state utilization, how much of this 26%, 27% should flow to our operating margins?
Utilization of what?
Of our clinic, sir like based on if it's like -- so is there a particular [indiscernible]?
Yes. So there is potential to increase the utilization without adding any extra cost. And that is what we are working on to improve the profitability of the business and we are investing in marketing for customer acquisition. So the infrastructure is there and the people are there and the utilization gap of the clinics remains more so during the weekdays and less so during the weekends when they are quite busy and therefore to improve profitability, we are working to improve the customer count and once we do that, it will come at no extra cost and flow directly to the bottom line.
Sir, can you give me a number about how much would be our utilization level currently?
We don't disclose that information in public domain. Should you like to have a person to person call, we can have that later on because it also varies significantly from clinic to clinic.
Okay, sir. Got it. Sir, next question was, sir, in our investor presentation, you have mentioned that the investment should grow at 13% over the next 5 years. And similarly, in your annual report, you have shown that it has grown by 13%, 14%, but we haven't been able to grow. Sir if I consider Kaya over the next 5 years, can we expect at least to grow at a rate that is faster than this industry level of 13%, 14%?
The management will be doing its best in order to improve the percentage of growth from what our current growth is 7%, 8% in quarter 1 and we are taking several initiatives. Like I mentioned, we are making extra investment in marketing and contribution. So we can try to get the growth from existing clinics without increasing costs further, so it flows to the bottom line. We are also as you may have heard started our expansion program. We believe that, that also will help us increase the top line without increasing the head office costs, and we can leverage the extra cost which should also help the profitability. So we believe that a combination of better utilization of our infrastructure and new clinics should help us improve the percentage of growth.
Got it. Sir, how are we measuring our...
I ask you to please come back to the queue for follow-up questions. The next question is from the line of [ Gaurang Wade ], an individual investor.
Sir, I just need a clarification. The last con call, you were talking about raising funds through right issue and up to around INR 300 crores. The quantum was changed to INR 75 crores and through the preferential route. So I just want to understand what was the thought process behind the change in plan? So can you please elaborate on that, please?
So we have -- as we have started our expansion program, we felt that the route to preferential allotment is simpler and quicker. So we have taken a strategic investor to come into the business with a high pedigree of performance and background that will support our growth. And in addition to that, post the preferential allotment is completed, which we are expecting by this month. The Board will then decide the way ahead on the rights issue.
Okay. So right, issue is still on or as of now it is postponed?
It's on the cards, but the decision will be taken by the Board post completion of the preferential issue.
Okay. And then the new invest coming in, a strategy in -- they will get the Board seat? Or it's not decided yet?
There is no decision on that yet.
Okay. And just one more question. I'll join back in the queue.
The next question is from the line of Eshit from Anvil.
One of my question was asked by the previous participant. Sir, again, adding to that, Isn't it fair that the existing investors of Kaya who have been with you for a longer time. We've given preference when there is a fundraising which is happening. Because right now, we've got a strategic investor, I understand we want to raise money faster. But for the existing investors, wouldn't rights be a more suitable option to raise money in the future?
We are in the process of completing the preferential allotment. And post that, the Board will decide on the way ahead on the rights issue. And like I mentioned, it's on the cards and we'll come back to you as soon as we are able to reach a decision.
In the AGM, I think you mentioned and even Mr. Mariwala mentioned about road to profitability with the kind of fund raise that we are looking at, a large part of our savings will be led through the interest cost savings that we'll also have because of this equity dilution. So what kind of new clinics we are targeting in order to drive revenue growth at the same corporate overhead level that we have today?
Look, it's a combination of -- it's going to be a combination of better utilization of existing infrastructure. And with the funds that we are going to receive, investments in marketing and customer acquisition is going to play a key part in that to drive the top line of existing clinics. And then as regards to the new clinics, as we mentioned, we've opened 2 in quarter 1. We've opened in quarter 2 already won, and we have 5 signed also. So by September, I think it will be around 8 -- September, October, it will be around 8 clinics. And then we -- and beyond that, we can't really give a forward-looking statement in terms of how many more we will open.
Sir, lastly Axana Estates, which is owned by Mithun Sacheti anything else he brings on the table apart from his experience in driving one of the largest online jewelry platform. Anything strategic for us?
May I request you to join the queue back for follow-up questions. The next question is from the line of Jitaksh Gupta from Tikri Investments.
I have 2 questions. First is, can you please give the revenue split between product and services? And second question, what is the current...
We got your first question, we can answer that for now and then... So the services is 85% of the business and product is 15%.
Okay. Can you...
Sorry to interrupt you, Mr. Jitaksh. Can you please come back in the queue. The next question is from the line of Madhur Rathi from Counter Cyclical Investments.
So I'm trying to understand, sir, our spend on marketing and branding, sir, how are we -- how are you like calculating the ROI? Or how are you calculating the incremental benefit that we are getting from these investments?
The investment in marketing is aimed to improve customer acquisition and drive new customers into the business. And that is how we calculate the ROI on that. Until last year, quarter 1, our customer count for new customer count was more or less negative. But now our performance marketing count has gone up by 6% so there is a change in the new customer count. And that's what we are trying to drive into our existing clinics. And once we drive that into our existing clinics, it should flow through the bottom line.
Mr. Madhur I will request you to join the queue back again for a follow-up questions. [Operator Instructions] Ladies and gentlemen, as there are no further questions, I now hand the conference over to management for closing comments.
Thank you for participating, and we appreciate the time you have taken to attend our investor call. Thank you.
Ladies and gentlemen, on behalf of Dolat Capital Markets Private Limited and Kaya, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.